Dillon Mueller Memorial Fund Helps Save Lives

Dillon Mueller on Dirt Bike

By the time he turned 18 years old, Dillon Mueller of Mishicot, Wisconsin had already spent years making an impression on his family, friends, and community.... He was an award-winning dirt bike racer since the age of 6, an Eagle Scout, and a member of Future Farmers of America....

Read the article here.

Allergies come in all shapes and sizes ...

Just like allergy sufferers. And they are on the rise. For many people allergies can range from sniffling and sneezing to skin rashes to gastrointestinal issues. A certain percentage, however, have more than these uncomfortable symptoms to deal with. Anaphylaxis, a serious life-threatening reaction, causes approximately 1,500 deaths a year in the United States alone. Clearly, allergies are nothing to sneeze at!

Articles for Advocacy

COVID-19 has certainly brought to everyone’s attention that people with asthma are at a greater risk of severe illness and hospitalization if they contract the virus. The Asthma and Allergy Foundation of America (AAFA) and the MedicAlert Foundation have joined forces to develop an online asthma or anaphylaxis treatment plan that will be part of a MedicAlert member’s health profile. In an emergency, MedicAlert will relay the action plan and other critical medical information to first responders to ensure fast and accurate treatment. If you have asthma or a life-threatening allergy, now is the time to get yourself a MedicAlert ID!

AAFA and MedicAlert© Foundation Announce a New Pact to Help Save Lives

AAFA logo
Medicalert Foundation logo

Partnership Raises Awareness of Asthma and Anaphylaxis

May 05, 2020
Source: Asthma and Allergy Foundation of America

Washington, D.C., May 05, 2020 (GLOBE NEWSWIRE) -- Over 65 million people in the United States live with asthma or allergies to food, drugs or other allergens. Tragically, 3,600 people die each year from asthma – deaths that are often preventable. COVID-19 poses additional danger to these populations. Two leading non-profits have joined forces to raise awareness and provide resources for living with these potentially life-threatening conditions: asthma and anaphylaxis.

Read the article here.

 

FARE (Food Allergy Research & Education) is proud to announce a new initiative called “Baby’s First” that hopes to reduce the number of children who have food allergies. New and soon-to-be parents will have access to all the best information on introducing new foods, available in one place from a trusted source. Studies now show that introducing a variety of foods into a baby’s diet is recommended, including peanut foods, if the infant is at risk for a peanut allergy. Always check with your baby’s doctor first!

FARE Launches Baby’s First: Reduce the Risk of Food Allergies

Baby's First logo

By  News Wire ~ 3rd Party Press Release

New Online Hub Dedicated to Raising Awareness and Educating New Parents

McLean, Va. (April 30, 2020) — Today, FARE (Food Allergy Research & Education), the world’s leading food allergy advocacy organization and the largest private funder of food allergy research, announced the launch of a new resource geared at raising awareness of the benefits of introducing a variety of new foods to babies and educating people on how they might be able to help reduce the risk of developing food allergies. 

Read the article here.

 

Everyone with allergies has probably experienced skin-prick tests and other assessments to find out exactly what they are allergic to. Today there is a new “ology” called molecular allergology that is innovating how allergies are diagnosed and treated. A routine blood test combined with molecular diagnostics will allow physicians to identify, with great specificity, the component proteins to which a patient is allergic. This new approach will also help gauge where a patient falls on the spectrum of possible reactions, so they will know what restrictions need to be put in place.

Transforming Allergy Diagnosis & Management

Physician Weekly logo

By Rebecca Rice
Apr 28, 2020

Researchers estimate that in the US, more than 50 million adults and 26 million children suffer from allergies every year, with an estimated $18 billion annually in associated costs to the healthcare system and businesses—with no end in sight, as the number of individuals affected by allergies continues to rise.

Historically, standard clinical management for allergies involved assessment of a patient’s reactions and history, followed by skin-prick testing, and/or immunoassays of whole allergen-specific immunoglobulin E (sIgE). The emerging field of molecular allergology is innovating how allergies are diagnosed and treated. Today, a routine blood test coupled with molecular diagnostics can allow physicians to identify, with great specificity, the component proteins to which a patient is sensitized.

Read the article here.

 

Upcoming Events

Google+

 

The information provided on this site is in no way intended to be a substitute for medical advice,
diagnosis, or treatment with a licensed physician.
The Allergy Advocacy Association is a 501(c)(3) non-profit, tax-exempt organization.
Copyright 2020 © Allergy Advocacy Association, Inc. All rights reserved.  Terms & Conditions